|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 45/06 | |
| A61P 35/00 |
| (11) | Number of the document | 3206491 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15851308.5 |
| Date of filing the European patent application | 2015-10-16 | |
| (97) | Date of publication of the European application | 2017-08-23 |
| (45) | Date of publication and mention of the grant of the patent | 2019-11-27 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2015/056060 |
| Date | 2015-10-16 |
| (87) | Number | WO 2016/061531 |
| Date | 2016-04-21 |
| (30) | Number | Date | Country code |
| 201462065550 P | 2014-10-17 | US | |
| 201562140876 P | 2015-03-31 | US | |
| 201562222746 P | 2015-09-23 | US |
| (72) |
MOSS, Jonathan, US
JOHNSON, Lorin K., US
|
| (73) |
Salix Pharmaceuticals, Inc.,
400 Somerset Corporate Boulevard, Bridgewater, NJ 08807,
US
The University of Chicago, 5801 South Ellis Avenue, Chicago, IL 60637, US |
| (54) | USE OF METHYLNALTREXONE TO ATTENUATE TUMOR PROGRESSION |
| USE OF METHYLNALTREXONE TO ATTENUATE TUMOR PROGRESSION |